story of the week
Neoadjuvant Letrozole + Taselisib vs Letrozole + Placebo in Postmenopausal Women With ER-Positive, HER2-Negative, Early-Stage Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant Letrozole Plus Taselisib Versus Letrozole Plus Placebo in Postmenopausal Women With Oestrogen Receptor-Positive, HER2-Negative, Early-Stage Breast Cancer (LORELEI): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
Lancet Oncol 2019 Aug 08;[EPub Ahead of Print], C Saura, D Hlauschek, M Oliveira, D Zardavas, A Jallitsch-Halper, L de la Peña, P Nuciforo, A Ballestrero, P Dubsky, JM Lombard, P Vuylsteke, CA Castaneda, M Colleoni, G Santos Borges, E Ciruelos, M Fornier, K Boer, A Bardia, TR Wilson, TJ Stout, JY Hsu, Y Shi, M Piccart, M Gnant, J Baselga, E de AzambujaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.